Providing Today's Patients with Medicines of the Future.
Staff
2017-2019 Net Profit CAGR
Current Brands of Products
Innovative Product Candidates
Covering Class III Hospitals
Covering Other Hospitals & Medical Institutions
Recently, the Phase III clinical trial for pediatric indication of Deunoxavir Marboxil, an innovative anti-influenza drug jointly developed by Simcere...
On August 29, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that the i...
On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tab...
On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreeme...